

Garching / Munich, Germany, September 9, 2021

ITM to Host Virtual Symposium at the ESMO Congress 2021 with Key Neuroendocrine Tumor Experts on September 17, 2021

[ITM AG](#), a leading radiopharmaceutical company, today announced that it will host a virtual industry satellite symposium titled, “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the European Society of Medical Oncology (ESMO) Congress 2021. The symposium will feature renowned key opinion leaders in the field and will be held on Friday, September 17th, 2021, from 10:30 am - 12:00 pm CEST on channel 3, open to ESMO registered participants.

The speakers are key precision oncology experts and will lead critical discussions addressing the changes within the treatment and diagnosis of neuroendocrine tumors. They will cover a range of topics examining the impact of NET diagnostic paradigms, treatment guidelines, and recent advancements within the clinical studies of Targeted Radionuclide Therapy. In addition to the ongoing COMPETE trial, the new phase III trial COMPOSE, a prospective study in high Grade 2 and Grade 3 gastroenteropancreatic NETs, will be presented. Participants will be able to interact with the speakers in a Q&A session at the end of the event.

Scientific Program and Participating Experts:

- **Welcome & Introduction**
Raj Srirajaskanthan, MD, FRCP King’s College Hospital, London, UK (5 mins)
- **Changes in the Incidence and Prevalence of NETs – Impact of New Diagnostic Paradigms**
Simon Singh, MD, MPH Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada (20 mins)
- **The Evolution of Guidelines for the Treatment of NETs**
Namrata Vijayvergia, MD, FACP Fox Chase Cancer Center, Philadelphia, U.S. (20 mins)
- **The Role of Targeted Radionuclide Therapy in Clinical Trials**
Grace Kong, MBBS (Hons), FRACP, FAANMS Peter MacCallum Cancer Center, Melbourne, Australia (20 mins)
- **Q&A and Closing Remarks** (25 mins)

For further information please visit ITM's ESMO 2021 Symposium [website](#) or the official ESMO [webpage](#).

- End -

About ITM Isotopen Technologien München AG

ITM, a privately held radiopharmaceutical biotech company founded in 2004, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radioisotope expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better. For more information, please visit www.itm-radiopharma.com.

ITM Corporate Contact

Susanne Karlsson
Interim Head of Marketing & Communications
Phone: +49 89 329 8986 1502
Email: susanne.karlsson@itm-radiopharma.com

ITM Media Requests

Trophic Communications
Stephanie May or Valeria Fisher
Phone: +49 171 185 56 82
Email: itm@trophic.eu

ITM Isotopen Technologien München AG

Executive Board: Steffen Schuster (CEO), Dr. Klaus Maleck (CFO) - Supervisory Board: Udo J Vetter (Chairman) - Registered Office: Garching/Munich
District Court of Munich - Commercial Register 154 944 - Phone: +49 (0)89 329 8986 600 - Fax: +49 (0)89 329 8986 650 - Email: info@itm-radiopharma.com
Tax Number: 143/100/82466 - VAT Number: DE813228901 - Deutsche Bank Freiburg - IBAN: DE52680700300022816300 - BIC: DEUTDE6F